Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases

Dawn M. Wahezi, Norman Todd Ilowite, Swapnil Rajpathak, Jacob H. Rand

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. The underlying mechanism(s) by which antiphospholipid antibodies (aPL) result in thrombosis remains poorly understood. A significant body of evidence has evolved to support the hypothesis that antibody-mediated disruption of an annexin A5 anticoagulant shield may play a role in the pathogenesis; this proposed mechanism has not been previously studied in children. Methods. We investigated the association between aPL and resistance to annexin A5 anticoagulant activity in 90 children with a variety of rheumatic diseases using a novel mechanistic assay, the annexin A5 resistance assay (A5R). Results. Patients with a diagnosis of primary aPL syndrome, systemic lupus erythematosus, and mixed connective tissue disease demonstrated lower mean A5R levels (p = 0.030), higher prevalence of positive aPL (p < 0.001), and more thrombotic events (p = 0.014) compared to those with other diagnoses. Patients with persistently positive aPL had significantly lower mean A5R compared to patients with no aPL (mean A5R = 203% ± 44% vs 247% ± 35%; p < 0.001), whereas patients with transient aPL did not. Patients with thrombosis had lower A5R levels compared to those without thrombosis (mean A5R = 207% ± 36% vs 237% ± 46%; p = 0.048). Conclusion. Children and adolescents with rheumatic diseases and persistent aPL have reduced annexin A5 anticoagulant activity, whereas transient, nonpathogenic aPL have less effect on annexin A5 activity. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)382-388
Number of pages7
JournalJournal of Rheumatology
Volume39
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Antiphospholipid Antibodies
Annexin A5
Rheumatic Diseases
Anticoagulants
Thrombosis
Mixed Connective Tissue Disease
Antiphospholipid Syndrome
Rheumatology
Systemic Lupus Erythematosus
Antibodies

Keywords

  • Annexin A5
  • Antiphospholipid antibodies
  • Pediatric rheumatic diseases
  • Pediatric systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases. / Wahezi, Dawn M.; Ilowite, Norman Todd; Rajpathak, Swapnil; Rand, Jacob H.

In: Journal of Rheumatology, Vol. 39, No. 2, 02.2012, p. 382-388.

Research output: Contribution to journalArticle

Wahezi, Dawn M. ; Ilowite, Norman Todd ; Rajpathak, Swapnil ; Rand, Jacob H. / Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases. In: Journal of Rheumatology. 2012 ; Vol. 39, No. 2. pp. 382-388.
@article{df963b9fe52443e39e2bdf475894609e,
title = "Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases",
abstract = "Objective. The underlying mechanism(s) by which antiphospholipid antibodies (aPL) result in thrombosis remains poorly understood. A significant body of evidence has evolved to support the hypothesis that antibody-mediated disruption of an annexin A5 anticoagulant shield may play a role in the pathogenesis; this proposed mechanism has not been previously studied in children. Methods. We investigated the association between aPL and resistance to annexin A5 anticoagulant activity in 90 children with a variety of rheumatic diseases using a novel mechanistic assay, the annexin A5 resistance assay (A5R). Results. Patients with a diagnosis of primary aPL syndrome, systemic lupus erythematosus, and mixed connective tissue disease demonstrated lower mean A5R levels (p = 0.030), higher prevalence of positive aPL (p < 0.001), and more thrombotic events (p = 0.014) compared to those with other diagnoses. Patients with persistently positive aPL had significantly lower mean A5R compared to patients with no aPL (mean A5R = 203{\%} ± 44{\%} vs 247{\%} ± 35{\%}; p < 0.001), whereas patients with transient aPL did not. Patients with thrombosis had lower A5R levels compared to those without thrombosis (mean A5R = 207{\%} ± 36{\%} vs 237{\%} ± 46{\%}; p = 0.048). Conclusion. Children and adolescents with rheumatic diseases and persistent aPL have reduced annexin A5 anticoagulant activity, whereas transient, nonpathogenic aPL have less effect on annexin A5 activity. The Journal of Rheumatology",
keywords = "Annexin A5, Antiphospholipid antibodies, Pediatric rheumatic diseases, Pediatric systemic lupus erythematosus",
author = "Wahezi, {Dawn M.} and Ilowite, {Norman Todd} and Swapnil Rajpathak and Rand, {Jacob H.}",
year = "2012",
month = "2",
doi = "10.3899/jrheum.110768",
language = "English (US)",
volume = "39",
pages = "382--388",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases

AU - Wahezi, Dawn M.

AU - Ilowite, Norman Todd

AU - Rajpathak, Swapnil

AU - Rand, Jacob H.

PY - 2012/2

Y1 - 2012/2

N2 - Objective. The underlying mechanism(s) by which antiphospholipid antibodies (aPL) result in thrombosis remains poorly understood. A significant body of evidence has evolved to support the hypothesis that antibody-mediated disruption of an annexin A5 anticoagulant shield may play a role in the pathogenesis; this proposed mechanism has not been previously studied in children. Methods. We investigated the association between aPL and resistance to annexin A5 anticoagulant activity in 90 children with a variety of rheumatic diseases using a novel mechanistic assay, the annexin A5 resistance assay (A5R). Results. Patients with a diagnosis of primary aPL syndrome, systemic lupus erythematosus, and mixed connective tissue disease demonstrated lower mean A5R levels (p = 0.030), higher prevalence of positive aPL (p < 0.001), and more thrombotic events (p = 0.014) compared to those with other diagnoses. Patients with persistently positive aPL had significantly lower mean A5R compared to patients with no aPL (mean A5R = 203% ± 44% vs 247% ± 35%; p < 0.001), whereas patients with transient aPL did not. Patients with thrombosis had lower A5R levels compared to those without thrombosis (mean A5R = 207% ± 36% vs 237% ± 46%; p = 0.048). Conclusion. Children and adolescents with rheumatic diseases and persistent aPL have reduced annexin A5 anticoagulant activity, whereas transient, nonpathogenic aPL have less effect on annexin A5 activity. The Journal of Rheumatology

AB - Objective. The underlying mechanism(s) by which antiphospholipid antibodies (aPL) result in thrombosis remains poorly understood. A significant body of evidence has evolved to support the hypothesis that antibody-mediated disruption of an annexin A5 anticoagulant shield may play a role in the pathogenesis; this proposed mechanism has not been previously studied in children. Methods. We investigated the association between aPL and resistance to annexin A5 anticoagulant activity in 90 children with a variety of rheumatic diseases using a novel mechanistic assay, the annexin A5 resistance assay (A5R). Results. Patients with a diagnosis of primary aPL syndrome, systemic lupus erythematosus, and mixed connective tissue disease demonstrated lower mean A5R levels (p = 0.030), higher prevalence of positive aPL (p < 0.001), and more thrombotic events (p = 0.014) compared to those with other diagnoses. Patients with persistently positive aPL had significantly lower mean A5R compared to patients with no aPL (mean A5R = 203% ± 44% vs 247% ± 35%; p < 0.001), whereas patients with transient aPL did not. Patients with thrombosis had lower A5R levels compared to those without thrombosis (mean A5R = 207% ± 36% vs 237% ± 46%; p = 0.048). Conclusion. Children and adolescents with rheumatic diseases and persistent aPL have reduced annexin A5 anticoagulant activity, whereas transient, nonpathogenic aPL have less effect on annexin A5 activity. The Journal of Rheumatology

KW - Annexin A5

KW - Antiphospholipid antibodies

KW - Pediatric rheumatic diseases

KW - Pediatric systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84856549517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856549517&partnerID=8YFLogxK

U2 - 10.3899/jrheum.110768

DO - 10.3899/jrheum.110768

M3 - Article

C2 - 22174207

AN - SCOPUS:84856549517

VL - 39

SP - 382

EP - 388

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -